Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: EXAS stock price vs ACAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Needs ACAD P/S.
Implied fair value · at EXAS's multiple
Needs EXAS P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXAS FY 2025 (ended Dec 31, 2025) · ACAD FY 2025 (ended Dec 31, 2025).
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
EXACT SCIENCES CORP · implied price per share
Bear
$0.03
Base
$0.03
Bull
$0.04
ACADIA PHARMACEUTICALS INC. · implied price per share
Bear
$5.79
Base
$6.81
Bull
$7.83
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
0.00x
Net debt / EBITDA
Leverage against operating earnings
-12.66x
-1.51x
Cash and equivalents
Liquid reserves on the balance sheet
$964.71M
$227.76M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Guardant Health, Inc.
EXAS vs GH
Natera, Inc.
EXAS vs NTRA
NEOGENOMICS INC
EXAS vs NEO
OPKO HEALTH, INC.
EXAS vs OPK
LABCORP HOLDINGS INC.
EXAS vs LH
QUEST DIAGNOSTICS INC
EXAS vs DGX
SUPERNUS PHARMACEUTICALS, INC.
EXAS vs SUPN
Sage Therapeutics, Inc.
EXAS vs SAGE
Jazz Pharmaceuticals plc
EXAS vs JAZZ
Alkermes plc.
EXAS vs ALKS
Harmony Biosciences Holdings, Inc.
EXAS vs HRMY
Krystal Biotech, Inc.
EXAS vs KRYS
$50.83M
$32.00K
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe EXAS can convert its 17.7% revenue growth and 69.7% gross margin into sustained positive operating margins, then EXAS is worth owning or accumulating because the current data imply upside only if profitability inflects meaningfully from the present -6.4% operating margin and -$207.9M net income.
On the provided P/S framework, EXAS is implied at $70.32 versus a ACAD-implied range of $16.23 to $70.32, which places it at the very top of the range. The valuation signal is therefore stretched relative to ACAD, but the lack of EXAS market price and missing multiple data limits precision.
Supporting Metrics
